Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  Through its 'Corporate Partnership Program', Bioscience Valuation has provided exceptional support in the transformation of our business model. BSV's evidence-based assessments proved invaluable for our strategic decision making as well as for preparing our corporate transactions.

Peter Llewellyn-Davies, CFO/CBO
Medigene AG

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Bioscience Valuation's News

Pharma companies are becoming increasingly aware of the importance of the continuing scientific education of their employees. If decision makers were to overlook this significant issue, scientists may find it harder than their academic peers to stay uptodate so as to be able to interact well with the broader context. This is immensely required for scientific progress.

View these Continued Education-certified talks that are accessible at HS Talks. (May 24, 2017)


Portfolio planning and risk management

Portfolio Planning and Risk Management
in the Pharmaceutical Industry 1


Dr. Joachim M. Greuel - Bioscience Valuation BSV GmbH, Germany



Portfolio planning and risk management

Portfolio Planning and Risk Management
in the Pharmaceutical Industry 1


Dr. Joachim M. Greuel - Bioscience Valuation BSV GmbH, Germany